## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%); PEG 2.08 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($551.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch**
- Source: TradingView — Track All Markets | 20251222T130936 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (TMO) has announced the enrollment of the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, an international initiative designed to generate real-world data on drug safety and effectiveness. This development is expected to support TMO stock's upward momentum despite a slight dip after the announcement, given the company's strong financial performance and the significant public health challenge posed by Alzheimer's disease. The registry aims to provide comprehensive insights into Alzheimer’s therapy outcomes, long-term safety, and treatment patterns.

**2. CCLA Investment Management Sells 16,843 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251222T100813 | Somewhat-Bullish | Relevance: 100%
- CCLA Investment Management decreased its holdings in Thermo Fisher Scientific Inc. by 5.3% in the third quarter, selling 16,843 shares. Despite CCLA's reduction, institutional ownership in Thermo Fisher remains high at 89.23%, with several other institutional investors significantly increasing their stakes. The company reported strong Q3 earnings, beating analyst estimates, and announced a new $5 billion share buyback program and a quarterly dividend.

**3. Analysts See 12% Upside To Thermo Fisher Scientific Inc. (TMO)**
- Source: Insider Monkey | 20251220T065600 | Bullish | Relevance: 100%
- Wall Street analysts have given Thermo Fisher Scientific Inc. (TMO) a consensus Strong Buy rating with a one-year average share price target of $640.30, indicating a 12% upside. Recent updates from Wells Fargo and Citigroup raised price targets, citing increased clarity on U.S. pharmaceutical policies, growth projections, and benefiting from onshoring trends and increased pharmaceutical spending. Despite modest 8% year-to-date returns in 2025, analysts are optimistic about the company's future performance.

**4. Thermo Fisher Scientific (TMO): Revisiting Valuation After New Alzheimer’s Registry and Ongoing Capital Deployment**
- Source: Simply Wall Street | 20251220T000923 | Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) recently enrolled a patient in its new PPD CorEvitas Alzheimer's Disease Registry, reinforcing its position in healthcare infrastructure. The stock has seen significant returns over the past 90 days and five years, suggesting rebuilding momentum. Despite trading near $567, it remains undervalued by approximately 6% intrinsically and 12% below consensus targets, prompting investors to assess if this is a good entry point.

**5. The Zacks Analyst Blog Highlights Walmart, Wells Fargo, Thermo Fisher Scientific, Seneca Foods and NetSol Technologies**
- Source: Yahoo Finance Singapore | 20251222T150904 | Bullish | Relevance: 100%
- This Zacks Analyst Blog highlights five key companies: Walmart Inc. (WMT), Wells Fargo & Co. (WFC), Thermo Fisher Scientific Inc. (TMO), Seneca Foods Corp. (SENEA), and NetSol Technologies, Inc. (NTWK). It discusses their recent financial performance, market outperformance, strategic initiatives, and identifies potential challenges and opportunities for each. The report emphasizes the unique microcap research provided for Seneca Foods and NetSol Technologies.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 9 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.08 elevated, pricing in significant growth expectations. Forward P/E 23.4x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (4 raises, avg +11%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $216.3B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.08 |
| Forward P/E | 23.4 |
| Current P/E | 25.3 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.0% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-1.70), momentum weakening. RSI neutral at 53. OFD pattern: +F0L (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.25% (CS: 56) | Neutral |
| RSI_14 | 53.1 | Neutral |
| MACD Histogram | -1.70 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.012x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $575.63
- **Stop Loss:** $551.39 (4.2% risk)
- **Target:** $599.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $28,205.87
- **Portfolio %:** 28.21%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*